Aptys pharma’s Post

Extremely topical #webinar today from Inpart ahead of #BIO2024 with helpful insights from J&J, especially on how #biotechs can improve both their outreach to and #partnering meetings with prospective #pharma #licensing partners. A few key points: 1. Focus on the science in your request for the meeting. 2. Clearly articulate how your science is novel and transformative, and the problem you're trying to solve. 3. Find a partner that shares your values. Look for a cultural fit that encourages a meaningful and long-term partnership.

🚀 Elevate Your Brand at BIO Europe 🌍 Are you ready to showcase your innovation to the world? 📈 The BIO Europe conference is a great stage for life science leaders, and One Nucleus is preparing the ON Helix Review for release at the conference. This could be the spotlight your company needs to shine brighter at BIO Europe and beyond. Prices start at just £500 + VAT for One Nucleus members. Why Sponsor the ON Helix Review? ✨ Unparalleled Visibility: Reach thousands of top-tier professionals and decision-makers in the international life sciences. ✨ Targeted Audience: Connect directly with your ideal customers, investors, and partners. ✨ Premium Placement: Stand out in a comprehensive review that attendees trust and reference. 📅 Don’t miss this golden opportunity to amplify your brand’s impact at one of the most influential events of the year. Secure your ad space now and be part of the conversation driving the future of life sciences. 🌟 Join us in transforming the future of life sciences and biotechnology. Your innovation deserves the spotlight! 🔗 Find out more here https://lnkd.in/eJ-TwrdB #BIOEurope #LifeSciences #Biotech #Innovation #Healthcare #BusinessGrowth #Marketing #Conference2024

🌟 We're back from the BIO International Convention in San Diego, and what an event it was! With over 20,000 global leaders in attendance, we had the opportunity to connect with our clients and build strong new partnerships across the biotech industry. Here are our top three key takeaways from the event: 1/ IPOs are making a comeback after a lull in 2022 and 2023. With about 80% currently trading below their issuance price, timing is key for success. 2/ Building a competitive biopharma ecosystem requires collaboration, incentives, a clear strategy, and streamlined implementation to foster innovation and efficiency. 3/ Rapid evolution in the landscape, with new assets and clinical trial designs, increases competition among clinical-stage biotechs for investment, and necessitates rethinking commercial growth strategies for PharmaCos. A big thank you to everyone who stopped by the Belgian Pavilion booth #4023 to meet our experts and discuss the latest trends shaping the future of R&D, operations, and commercial strategies. Let’s continue the conversations and help unlock the full potential of your organisation with our deep industry knowledge and sector expertise. 👉 Discover more about how we can support your growth: https://pwc.to/3UXaWRE #BIO2024 #biotech #pharma #PwCBelgium

🌟 We're back from the BIO International Convention in San Diego, and what an event it was! With over 20,000 global leaders in attendance, we had the opportunity to connect with our clients and build strong new partnerships across the biotech industry. Here are our top three key takeaways from the event: 1/ IPOs are making a comeback after a lull in 2022 and 2023. With about 80% currently trading below their issuance price, timing is key for success. 2/ Building a competitive biopharma ecosystem requires collaboration, incentives, a clear strategy, and streamlined implementation to foster innovation and efficiency. 3/ Rapid evolution in the landscape, with new assets and clinical trial designs, increases competition among clinical-stage biotechs for investment, and necessitates rethinking commercial growth strategies for PharmaCos. A big thank you to everyone who stopped by the Belgian Pavilion booth #4023 to meet our experts and discuss the latest trends shaping the future of R&D, operations, and commercial strategies. Let’s continue the conversations and help unlock the full potential of your organisation with our deep industry knowledge and sector expertise. 👉 Discover more about how we can support your growth: https://pwc.to/3UXaWRE #BIO2024 #biotech #pharma #PwCBelgium

🌟 We're back from the BIO International Convention in San Diego, and what an event it was! With over 20,000 global leaders in attendance, we had the opportunity to connect with our clients and build strong new partnerships across the biotech industry. Here are our top three key takeaways from the event: 1/ IPOs are making a comeback after a lull in 2022 and 2023. With about 80% currently trading below their issuance price, timing is key for success. 2/ Building a competitive biopharma ecosystem requires collaboration, incentives, a clear strategy, and streamlined implementation to foster innovation and efficiency. 3/ Rapid evolution in the landscape, with new assets and clinical trial designs, increases competition among clinical-stage biotechs for investment, and necessitates rethinking commercial growth strategies for PharmaCos. A big thank you to everyone who stopped by the Belgian Pavilion booth #4023 to meet our experts and discuss the latest trends shaping the future of R&D, operations, and commercial strategies. Let’s continue the conversations and help unlock the full potential of your organisation with our deep industry knowledge and sector expertise. 👉 Discover more about how we can support your growth: https://pwc.to/3UXaWRE #BIO2024 #biotech #pharma #PwCBelgium

🌟 We're back from the BIO International Convention in San Diego, and what an event it was! With over 20,000 global leaders in attendance, we had the opportunity to connect with our clients and build strong new partnerships across the biotech industry. Here are our top three key takeaways from the event: 1/ IPOs are making a comeback after a lull in 2022 and 2023. With about 80% currently trading below their issuance price, timing is key for success. 2/ Building a competitive biopharma ecosystem requires collaboration, incentives, a clear strategy, and streamlined implementation to foster innovation and efficiency. 3/ Rapid evolution in the landscape, with new assets and clinical trial designs, increases competition among clinical-stage biotechs for investment, and necessitates rethinking commercial growth strategies for PharmaCos. A big thank you to everyone who stopped by the Belgian Pavilion booth #4023 to meet our experts and discuss the latest trends shaping the future of R&D, operations, and commercial strategies. Let’s continue the conversations and help unlock the full potential of your organisation with our deep industry knowledge and sector expertise. 👉 Discover more about how we can support your growth: https://pwc.to/3UXaWRE #BIO2024 #biotech #pharma #PwCBelgium

Early Bird rates for Bio€quity Europe ends Friday - register now to save! With 60+ biotechs already confirmed to present, this year’s event in San Sebastián is expected to sell out, again. In fact, we are on track to exceed last year, when 300 VCs, 330 CEOs, and 150 C-level executives joined. This year we will gather in Basque Country to discuss how biotechs can rise above the noise to attract the right investors, partners, and talent. I hope you will join BioCentury Inc., EBD Group, and Regional Host Committee Chair Ysios Capital in one of the culinary capitals of the world. Register for #BioEquityEurope by Friday to save: https://ow.ly/lkOl50QyYeS Learn more, including the schedule-at-a-glance and presenting companies you will meet: https://ow.ly/8B5c50QyYeR #biotech #biopharma

Dear network, 🌟 We're back from the BIO International Convention in San Diego, and what an event it was! With over 20,000 global leaders in attendance, we had the opportunity to connect with our clients and build strong new partnerships across the biotech industry. Here are our top three key takeaways from the event: 1/ IPOs are making a comeback after a lull in 2022 and 2023. With about 80% currently trading below their issuance price, timing is key for success. 2/ Building a competitive biopharma ecosystem requires collaboration, incentives, a clear strategy, and streamlined implementation to foster innovation and efficiency. 3/ Rapid evolution in the landscape, with new assets and clinical trial designs, increases competition among clinical-stage biotechs for investment, and necessitates rethinking commercial growth strategies for PharmaCos. A big thank you to everyone who stopped by the Belgian Pavilion booth #4023 to meet our experts and discuss the latest trends shaping the future of R&D, operations, and commercial strategies. Let’s continue the conversations and help unlock the full potential of your organisation with our deep industry knowledge and sector expertise. 👉 Discover more about how we can support your growth: https://pwc.to/3UXaWRE #BIO2024 #biotech #pharma #PwCBelgium

Come and talk to us about your plans and challenges in drug development #pharma #drugdevelopment

Along with colleague Marit Hvithamar Rystrøm we were invited to present the European Biosolutions Coalition at the #SwissBiotechDay2024 We are here in close cooperation with economiesuisse one of our founding partners in the Coalition 🇨🇭 Thank you for having us Michael Altorfer and for the fruitful discussion on how we can promote biosolutions in Europe 🇪🇺 Biosolutions might represent a smaller green dot 🟢 in the sea of red biotech 🔴 as my colleague Marit writes, but it is an important and growing sector across Europe and we have common ambitions. The European market is important for all of us and we agree on the urgency for Europe to speed up the recognition process of new biosolutions to achieve more sustainability, competitiveness and resilience in Europe🤞 We should move from biosolutions companies which are now born in Europe but often grow up elsewhere to companies which want to stay and grow in Europe 🌱 The more partners we are to push for change the better 🤝 #biosolutions #sustainability #competitiveness #resilience